Target intelligence / Profile preview

Fructosamine-3-kinase-related protein (FN3KRP)

Target
FN3KRP
Molecular classification
Enzyme, Protein kinase, Transferase (specifically, phosphorus-containing groups)
01

Overview

Fructosamine-3-kinase-related protein (FN3KRP) is an enzyme found in humans and encoded by the FN3KRP gene (HGNC:25700). It belongs to the protein kinase family, sharing strong sequence similarity with fructosamine-3-kinase (FN3K), but it differs in substrate specificity. FN3KRP catalyzes the phosphorylation of ketosamines such as psicosamines and ribulosamines generated by non-enzymatic glycation (fructation) of proteins, rather than the Amadori products phosphorylated by FN3K. Its physiological role is believed to be the breakdown or removal of non-enzymatic fructation products from proteins, contributing to protein quality control and cellular metabolism. This function has implications for the regulation of the biological Maillard reaction and protein repair, but the exact metabolic substrates and disease relevance remain incompletely established[1][2][6]. FN3KRP is highly conserved across vertebrates and is constitutively expressed, underscoring its suspected importance in cellular homeostasis[1][5][6].

Other names
Ketosamine-3-kinaseFN3K-RPFN3K-related proteinFLJ12171FN3KLFructosamine-3-kinase-related proteinProtein-psicosamine 3-kinaseProtein-ribulosamine 3-kinaseTestis secretory sperm-binding protein Li 211a
02

Mechanism of action

If therapeutically targeted, inhibition or activation would likely affect cellular deglycation processes by modifying phosphorylation of non-enzymatic glycation products on proteins (ribuloselysine, psicoselysine)[1][2][6].

03

Biological functions

Protein deglycationPhosphorylation of ketosamine adducts (psicosamines, ribulosamines)Cellular metabolic regulationPotential involvement in protein repair by removing glycation modifications[1][2][6]
04

Disease associations

There is no direct, well-established link to specific diseases, but dysregulation of protein glycation is broadly implicated in conditions like diabetes and aging. FN3KRP’s role in protein deglycation could suggest secondary relevance in metabolic and degenerative diseases[1][2].
05

Safety considerations

No known safety concerns or therapeutic challenges are reported for targeting FN3KRP due to the lack of drug development programs against this protein[2][5].
06

Interacting drugs

No approved or investigative drugs are presently documented to specifically target FN3KRP in public databases or literature[2][6].
07

Biomarkers

No validated biomarkers directly linked to FN3KRP for patient selection or efficacy monitoring are documented[2][5].

Beyond the preview

Go deeper on Fructosamine-3-kinase-related protein (FN3KRP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fructosamine-3-kinase-related protein (FN3KRP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call